In March, 2024, the FDA granted Fast Track designation for elritercept (KER-050, Keros Therapeutics Inc.) to treat anemia in adult patients with very low-, low-, or intermediate-risk MDS.
Anemia, which is a reduced red blood cells counts, is a common condition that affects 90% of MDS patients. Some require transfusions, and others experience significant quality-of-life impacts due to anemia’s common symptoms, like fatigue. Expanding treatments for anemia in MDS patients will help reduce the symptom burden and risks that transfusion therapy has.
The FDA's Fast Track process facilitates the development of investigational treatments that demonstrate the potential to address medical needs in serious conditions.
Elritercept is currently is in a Phase 2 clinical trial, still enrolling for lower-risk MDS patients.
As elritercept progresses through clinical trials, it could lessen the reliance on transfusion therapy, enhance quality of life, and reduce the risks associated with long-term anemia management. These developments bring hope to patients and healthcare providers, signaling a positive trajectory in addressing the challenges posed by anemia in MDS.
If you want to continue reading about MDS, you can check our 101 articles, like:
Subscribe to our newsletter to stay updated on the latest MDS news!
In March, 2024, the FDA granted Fast Track designation for elritercept (KER-050, Keros Therapeutics Inc.) to treat anemia in adult patients with very low-, low-, or intermediate-risk MDS.
Anemia, which is a reduced red blood cells counts, is a common condition that affects 90% of MDS patients. Some require transfusions, and others experience significant quality-of-life impacts due to anemia’s common symptoms, like fatigue. Expanding treatments for anemia in MDS patients will help reduce the symptom burden and risks that transfusion therapy has.
The FDA's Fast Track process facilitates the development of investigational treatments that demonstrate the potential to address medical needs in serious conditions.
Elritercept is currently is in a Phase 2 clinical trial, still enrolling for lower-risk MDS patients.
As elritercept progresses through clinical trials, it could lessen the reliance on transfusion therapy, enhance quality of life, and reduce the risks associated with long-term anemia management. These developments bring hope to patients and healthcare providers, signaling a positive trajectory in addressing the challenges posed by anemia in MDS.
If you want to continue reading about MDS, you can check our 101 articles, like:
Subscribe to our newsletter to stay updated on the latest MDS news!
about the author
Jimena Vicencio
Jimena is an International Medical Graduate and a member of the HealthTree Writing team. She has a passion for languages and is currently learning Japanese. In her free time, she loves playing with her cats. Jimena is also pursuing a bachelor's degree in journalism.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.